

# Update on Emergency Use Listing

Mariângela Simão
Rogério Gaspar

25 November 2021

# EUL process


STEP 1
Expression of Interest
-Submission by company
-Assessment
-Response (positive/negative)
NEGATIVE
Company must resubmit
STEP 2
Pre-submission meeting
-Company presents product information
- Timelines for rolling submissions
STEP 3
Establishment of PEG
(Product Evaluation Group)-Roster expert + reviewers from NRAs (CMC/non-clinical/clinical/RMP)
Designation of Focal Points for CMC and non-clinical/clinical
Invitation
Signature of DoI and CA
Access to Sharepoint
Briefing
STEP 4
Screening of the submission/Assessment by PEG
- LOQs
- Responses
- PEG report
Review of data packages
GMP Inspection/recognition
STEP 5
TAG assessment of PEG report and recommendation
TAG deliberation and recommendation
Sharing approved version of RMP with
PVG for implementation of post listing activities
STEP 6
Public Assessment Report
Announcement of Outcome
STEP 7
Post Listing activities
- Updates
- Changes
- Surveillance reports

# WHO SARS-CoV-2 IVDs recommended for Emergency Use Listing (EUL)

update: as of 23 Nov 2021




| | Test types | | |
|---|---|---|---|
| **Total** | Nucleic acid | Antibodies | Antigen |
| **>200** | *(split not available)* | | |
| **165** | 67 | 41 | 57 |
| **78** | 16 | 28 | 37 |
| **28** | 23 | 1 | 4 |
| **48** | 27 | 10 | 11 |

EUL maintenance

**EUL Renewals**
24 under review

**Change Requests**
21 under review

# WHO SARS-CoV-2 IVDs: Increasing support for EUL assessment

update: as of 23 Nov 2021

**Expanding expert network**

- Expert assessors from trusted partners
- Leverage reliance mechanisms where appropriate
- Support for EUL dossier screening & review

**Training for EUL assessment**

- WHO PQ-IVD Team to host EUL Workshops for new assessors
- *EUL requirements; good assessment & reporting practice*
- Q&A sessions with expert review teams

**Increasing assessment capacity**

- Expanded pool of technical experts ready to support EUL from Q1 2022
- Increased number of EUL applications reviewed

**With collaborating partners**

ANVISA (Brazil)
CDC (USA)
FDA (USA)
HSA (Singapore)
MFDS (Rep Korea)
NRL (Australia)
PEI (Germany)

# WHO Emergency Use Listed Covid-19 vaccines

World Health Organization

update: as of 19 Nov 2021

| Platform | Manufacturer / EUL holder / name | NRA of Record | Post-EUL commitments |
|---|---|---|---|
| mNRA-based vaccine encapsulated in lipid nanoparticle (LNP) | BioNTech Manufacturing GmbH BNT162b2 / COMIRNATY: Tozinameran | EMA, US FDA | • Chemistry Manufacturing Control (CMC) updates<br>• Clinical<br>• Updated data on the efficacy/effectiveness<br>• Updated Risk Management Plan (RMP)<br>• Monthly safety reports, and Periodic Benefit Risk Evaluation Reports (PBRER) every 6 months<br>• Updated labelling, shipping validation (if applicable) and data for vaccine vial monitors (VVM)<br>• Others |
| | Moderna Biotech, mRNA-1273: elasomeran | EMA, US FDA | |
| Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 | AstraZeneca, AB: AZD1222 Vaxzevria | EMA, Health Canada, MFDS, MHLW-PMDA, TGA | |
| | Serum Institute of India Pvt. Ltd: Covishield (ChAdOx1_nCoV-19) | DCGI | |
| Recombinant, replication-incompetent adenovirus type 26 vectored vaccine encoding the SARS-CoV-2 Spike (S) protein | Janssen–Cilag International NV: Ad26.COV2.S | EMA | |
| Inactivated, produced in Vero cells | Sinopharm / Beijing Institute of Biological Products Co., Ltd. (BIBP) | NMPA | |
| | Sinovac Life Sciences Co., Ltd.: Coronavac™ | NMPA | |
| | Bharat Biotech: BBV152 COVAXIN® | DCGI | |

# Other Covid 19 vaccines under EUL

update: as of 16 Nov 2021

World Health Organization

| # | Manufacturer / WHO EUL holder | NRA of Record | Status | meetings | Rolling data | | |
|---|---|---|---|---|---|---|---|
| 13. | NOVAVAX | EMA | ✓ | ✓ | Rolling data in Sept and end October 2021 Meeting with EMA and MHRA | Ongoing | |
| 14. | SERUM INSTITUTE OF INDIA PVT. LTD. Covovax | DCGI India | ✓ | ✓ | Rolling data aligned with core data | Ongoing | |
| 15. | THE GAMALEYA NATIONAL CENTER | Russian NRA | Additional information submitted | Several meetings have been and continue to be held. | "Rolling" data of clinical and CMC has started. | Additional data (Non-CLIN, CLIN, CMC) Required. Following up on inspection observations. | Anticipated date will be set once all data is submitted and follow-up of inspection observations completed. |
| 16. | 康希诺生物 CanSinoBIO | NMPA China | ✓ | ✓ | Rolling data started 09 Aug 2021 | Ongoing | |
| 17. | Sinopharm / W | NMPA China | ✓ | | Rolling data in Aug 2021 | Ongoing | |
| 18. | Sanofi Pasteur | EMA | ✓ | ✓ | Sept-Nov/Dec 2021 | Ongoing | |
| 19. | Clover Biopharmaceuticals | NMPA China | ✓ | ✓ | Rolling data started 20 September | Ongoing | |
| 20. | Vector State Research Centre of Viralogy and Biotechnology | Russian NRA | Letter received not EOI. Reply sent on 15/01/2021 | Q4 2021 | | | |
| 21. | Zhifei Longcom, China | NMPA China | Response to 2nd EOI sent 29 Jan 2021. Additional info requested. | Meeting being planned | | | |
| 22. | IMBCAMS, China | NMPA China | Not accepted, still under initial development | | | | |
| 23. | BioCubaFarma - Cuba | CECMED Cuba | Awaiting information on strategy and timelines for submission. | | | | |

# WHO Support to regions & countries

update: as of 23 Novemebr 2021

WHO EUL assessment with designate lead NRAs in the region

Facilitating national approvals by sharing regulatory dossiers

- Product Evaluation group (PEG):
  Roster of regulatory experts from all 6 regions
- Technical Advisory group (TAG-EUL):
  Risk benefit assessment
  ToR and list of members
- Collaboration agreement with NRAs of references and others on regulatory oversight

1. Sharing dossier and EUL reports
   - >400 reports shared with >100 countries (both LMIC & HIC)
2. Discussion on outcome of review:
   - Facilitated workshops
   - One-on-one discussions with countries
3. Additional guidance for decision making on expedited authorization
   - Support to RO and agencies providing relevant docs for actual shipments
4. Post listing changes:
   - > 152 changes (clinical, CMC, labelling, packaging, shelf-life, new sites, etc.)

# Emergency regulatory authorizations issued by 122 LMICs

update: as of 16 Nov 2021




(*source: COVAX platform*)




# WHO Therapeutics and COVID-19: Living Guideline*

## Latest update issued on 24 Sept 2021

World Health Organization

| | | |
|---|---|---|
| 2021 09 24 | conditional recommendation to use a combination of neutralizing monoclonal antibodies (casirivimab & imdevimab)** | in non-severe COVID-19 patients at the highest risk of severe disease |
| | conditional recommendation to use a combination of neutralizing monoclonal antibodies (casirivimab & imdevimab)** | in severe and critically ill COVID-19 patients with seronegative status |
| 2021 07 06 | strong recommendation to use IL-6 receptor blockers (tocilizumab or sarilumab)** | in patients with severe or critical COVID-19 |
| 2021 03 31 | recommendation not to use ivermectin | in patients with COVID-19 except in the context of a clinical trial |
| 2020 12 17 | strong recommendation against hydroxychloroquine | in patients with COVID-19 of any severity |
| | strong recommendation against lopinavir/ritonavir | in patients with COVID-19 of any severity |
| 2020 11 20 | conditional recommendation against remdesivir | in hospitalized patients with COVID-19 |
| 2020 09 02 | strong recommendation for systemic corticosteroids** | in patients with severe and critical COVID-19 |
| | conditional recommendation against systemic corticosteroids | in patients with non-severe COVID-19 |

*WHO Therapeutics and COVID-19: Living Guideline

**Expression of interest for Prequalification

# Therapeutics: The 5th and current EOI for prequalification (PQ)

| | EoI issued for PQ | | applications |
|---|---|---|---|
| Molnupiravir | 15 Nov 2021 | | One application received |
| Casirivimab and imdevimab | 21 Sep 2021 | generic/biosimilar versions invited | |
| Tocilizumab and sarilumab | 19 May 2021 | generic/biosimilar versions invited | One application under assessment |
| Dexamethasone | 10 July 2020 | | 2 FPPs and 2 APIs prequalified in 2020/2021 |

Ongoing engagement with innovator and generic/biosimilar manufacturers to clarify requirements and address questions (examples below)

- Whether the safety/efficacy of generic products can be supported with biowaiver data instead of bioequivalence
- If PQ would accept less stability data than usual at the time of submission
- for biotherapeutics approved by SRAs, how to adapt packaging, transport conditions and pharmacovigilance risk management plans to LMIC settings
- for biosimilars, how to show biosimilarity, how to characterize the molecule etc.
- how to facilitate country approvals of prequalified or SRA approved products

# Therapeutics: Next steps

- All therapeutics invited are eligible for submission for prequalification.

  EUL to be activated when needed.

- Continuing monitoring of pipelines (Paxlovid, other antibodies) and interaction with ACT-A and WHO Clinical Management Team in preparation for possible invitation of new therapeutics, including engagement with the respective manufacturers.

- Preparations ongoing with GF and UNICEF to use the ERP risk assessment mechanism for molnupiravir generic products - to make products available promptly while they progress towards prequalification.